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clinical manifestation, antibiotic susceptibility and treat-
ment.
Methods: A retrospective study was conducted during the
period January 2007—Febrary 2008 to detected CA-MRSA
isolated from samples of SSTI obtained from HIV positive
patients attended at the ambulatory care Infectious Diseases
Unit at Fernandez Hospital in Buenos Aires, Argentina. We
registered 13 positive samples but 2 were excluded from
the analysis because of hospitalization during the previous
6 month. Epidemiological features, clinical manifestation,
antibiotic susceptibility, treatment and outcome were eval-
uated.
Results: n = 11, F/M 4/7, median age = 37yrs (r19—49),
heterosexual 27%, MSM 27%, IDU 27%. Median CD4 count
258 cell/mm3 (r10—382), 5 were on HAART. Clinical man-
ifestation: furunculosis 73%, folliculitis 18% and cellulitis
9%. During the previous 6 month to the episode: 6 had
received ATB (4 beta-lactams and 2TMP/SMX). The antibi-
ogram showed: macrolide resistance 54% and clindamycin
resistance 18%. No rifampicin, ciproﬂoxacin or TMP/SMX
resistance was detected. The empirical treatment was inad-
equate in 70%; median of treatment duration 8 days (r7—14).
None of the patients required surgical drainage and the out-
come was favorable in all of them.
Conclusion: CA-MRSA must be considered a possible eti-
ology of SSTI in this population; especially in patients with
furunculosis witch was the most frequent clinical manifes-
tation. We detected 18% of clindamycin resistance and the
absence of TMP/SMX, ciproﬂoxacin or rifampicin resistance.
The active surveillance of methicillin associated resistance
is important to guide the adequate empirical antibiotic ther-
apy in patients with possible CA-MRSA lesion.
doi:10.1016/j.ijid.2008.05.606
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Background: Pneumonia is a leading cause of mortality in
the developing world. Many recent studies have suggested
that low-cost and minimally invasive interventions are crit-
ical in reducing mortality in severely ill infants and children
in resource-limited settings. We hypothesize that CPAP, used
aggressively, will decrease intubations and improve the mor-
tality of patients diagnosed with severe pneumonia who are
admitted to the intensive care unit (ICU) of Angkor Hospital
for Children (AHC) in Cambodia.
Methods: AHC’s ICU patient log book was reviewed for
the year 2005 and all patients were placed in a database
according to diagnosis, intubation, and mortality. The avail-
able evidence was reviewed and an evidence-based protocol
for CPAP was developed by the local Cambodian staff. The
protocol was implemented in January 2006 and data was col-
lected prospectively on diagnosis, intubation, CPAP use, and
mortality for the year 2006.
Results: In 2005 and 2006, 101 and 151 patients were
admitted respectively with a primary and sole diagnosis of
pneumonia. In 2006 compared to 2005, intubations among
these patients decreased by 47% and mortality decreased by
77%.
Conclusion: Early intervention with a minimally invasive,
low-cost, evidence based CPAP protocol reduces intubation
and improves mortality in patients with pneumonia present-
ing to a children’s hospital in a resource-limited setting.
doi:10.1016/j.ijid.2008.05.607
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Background of the study: Several HIV-1 infected patients
show bone loss and osteopenia/osteoporosis during the
course of disease. The mechanisms underlying this degen-
erative process are largely unsettled and the relationship
between HIV-1 and osteoblasts/osteoclasts cross-talk regu-
lation has not been yet investigated. The aim of our study
is focused on analysis of biological effects of HIV-1 on
osteoblasts and osteoblast-like HOBIT cells to determine the
mechanisms involved in the bone loss in the course of HIV-1
infection.
Methods used: Human hipbone osteoblasts of patients
were obtained from commercial sources or isolated from
HIV-1 negative patients enrolled after giving their informed
consent. HIV-1 DNA was determined by PCR whereas RT-
PCR was employed to determine viral RNA, cell membrane
markers and TNF-alfa mRNA.
Results: proviral HIV-1 PCR analysis showed that pri-
mary osteoblasts and HOBIT osteoblast-like cell line are
not susceptible to infection. On the other hand, HIV-1,
heat-inactivated HIV-1 and HIV-1 gp120 treatment induced a
signiﬁcant apoptotic process activation at 72—96 hours that
is tackled by soluble CD4 treatment suggesting an interac-
tion between gp120 and cell membrane proteins.
Although the CD4 and CXR4 mRNA was costantly
detectable in both the cell models, CD4 and CXR4 proteins
are expressed at very low density in a low percent-
age of cells (4—6% and 4% respectively) whereas CCR5
is signiﬁcantly more expressed. HIV-1, heat-inactivated
HIV-1 and HIV-1 gp120 treatment induced both the
TNF-alfa mRNA and supernatant protein increase at
24—96 hours. Moreover, anti-TNF-alfa pretratment tack-
les the apoptosis induction suggesting a direct role of
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TNF-alfa in the HIV-1 related activation of apoptotic pro-
cess.
Conclusions: These results indicate that HIV-1 triggers
apoptosis in osteoblasts and HOBIT cells through the gp120
interaction with cell membrane and TNF-alfa induction sug-
gesting a novel mechanism in the HIV-1 related impairment
of the bone mass structure homeostasis.
doi:10.1016/j.ijid.2008.05.608
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Objective: To compare the Tumor Necrosis Factor-alpha
(TNF-) levels in HIV infected and uninfected healthy indi-
viduals and to evaluate TNF- release in the presence of
Vitamin D3, EB 1089 and methyl prednisolone in whole blood
cell cultures of HIV infected and uninfected individuals.
Methods: Plasma TNF- estimation: Blood was collected
from healthy blood donors (n = 66) & HIV infected patients
(n = 71) after their consent. Plasmawas separated and stored
at -700C till TNF- levels were measured.
Whole Blood cell assay: TNF- release was evaluated
in whole blood cell cultures of HIV infected (n = 13) and
uninfected individuals (n = 7) with and without modulators
such as Phytohaemagglutin (PHA) and Concanavalin-A (Con-
A); Methylprednisolone sodium succinate, Vitamin D3 and
EB1089 all of which have a potential affect on TNF- release.
Cytokine assay: The TNF- levels were estimated by
sandwich ELISA using R& D systems kit.
Results: There was a wide range of values of TNF- lev-
els in individuals of both uninfected and HIV infected groups.
There was a signiﬁcant decrease in the plasma TNF- levels
in HIV infected as compared to uninfected group. Stimula-
tion of whole blood cell cultures by Con A & PHA did not
show signiﬁcant differences in the TNF- release between
uninfected and HIV infected individuals. When stimulated
whole blood cultures were incubated in the presence of
methylprednisolone, vitamin D3 and EB 1089, only methyl-
prednisolone showed signiﬁcant difference in the inhibition
pattern as compared to others.
Conclusion: There is a wide scatter of individual plasma
TNF- values in patients & normal individuals. TNF- release
in the whole blood assays of normal & HIV patients also
showed a wide variation. Methylprednisolone exerted max-
imum inhibition in TNF- release as compared to other
modulators. Clinical follow up and longitudinal studies on
TNF- levels in patients could indicate its role in the pro-
gression of HIV to AIDS.
doi:10.1016/j.ijid.2008.05.609
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Approximately 10—40% of HIV-infected patients respond-
ing to antiretroviral therapy (ART) develop immune
restoration disease (IRD). It is thought that patients experi-
ence clinical deterioration as a result of an inﬂammatory
response to intact subclinical pathogens and/or residual
antigens.
Objective: To determine the incidence and risk factors
for the development of IRD in a cohort of severely immuno-
suppressed patients during successful treatment with ART
(triple therapy) at the UMMC clinic.
Methods: Patients were monitored and clinical data char-
acterized at weeks 0, 6, 12, 24 and 48 of ART from 47
patients with age, gender, ethnicity, CD4 T-cell count and
percentage, and plasma HIV RNA.
Results: The incidence of IRD in our cohort was 27.7%,
and the commonest IRD event was an exacerbation of symp-
toms (cervical lymphadenitis, lymphadenopathy and lymph
nodes evolving into abscesses or cold abscess enlargement)
associated with pre-existing infections with Mycobacterium
tuberculosis (MTb). Having a low baseline CD4 T-cell count
and percentage was a risk factor for developing IRD. TB IRD
occurred in patients who started ART within 6 weeks of TB
treatment.
Conclusion: Patients with advanced disease initiating ART
must be closely monitored in the ﬁrst 6 months for develop-
ment of IRD. In areas where MTB is endemic, TB IRD may
occur frequently and lead to diagnostic and therapeutic
challenges.
doi:10.1016/j.ijid.2008.05.610
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Objectives: A proportion of HIV patients beginning
antiretroviral therapy (ART) develop immune restoration
disease (IRD). Immunological characteristics of IRD were
